




CAPTAIN T CELL

Next-generation T cells for solid tumor patients

COMPANY DECK

MAX
DELBRÜCK
CENTER

Spin-off from renowned research institute



13 highly dedicated FTEs



Branch in **Berlin**, Germany


Dr. Felix Lorenz, CEO/CSO

felix.lorenz@captaintcell.com

MARKET

Targeting multi-billion \$ market of solid tumor patients with limited treatment options

TUMOR ANTIGEN (MAGE-A4+)



Lung cancer
Bladder cancer
Esophageal cancer
Head and neck cancer
Ovarian cancer
Gastric cancer
Synovial sarcoma

CANCER DEATHS/YR (MAGE-A4+ in US, EU, UK)

95,000

800



CAPTAIN T CELL

12,000

COMPETITION

Adaptimmune's **Tecelra**

- FDA-approved TCR-T cells (2024)
- **TAM: 800 pts** (syn. sarcoma, HLA-A2)
- Not sufficiently efficacious in larger indications

MARKET (MAGE-A4a/HLA-A1)



- Targeted by Captain T Cell's lead program CTC127
- **TAM: 12,000 pts/yr**
- **Best-in-class efficacy** compared to competition

REVENUE POTENTIAL




- One-time treatment costs \$727,000
- Treating only 1,400 (15%) of TAM generates \$1B sales

SOLUTION

Increasing efficacy of AUTO TCR-T cells for targeting difficult-to-treat solid tumors

Preclinical A375 mouse model




DIFFERENTIATION

Best-in-class efficacy of TCR-T cells for targeting difficult-to-treat solid tumors


Preclinical A375 mouse model

(T cells + TCR/AFFINITY + CO-RECEPTOR + SWITCH + PHENOTYPE)



Preclinical A375 mouse model

(T cells + TCR/AFFINITY)




DIFFERENTIATION

1. Higher potency makes it suitable for difficult-to-treat indications
2. Automated scalable manufacturing (reducing COGS by 50%)
3. Distinct patient population (HLA-A1 vs. HLA-A2)

HOLY GRAIL

Inducing complete responses with first-in-class allogeneic (off-the-shelf) TCR-T cell platform

Preclinical A375 mouse model




- TCR-ALLO cells + TOOLBOX + X (n=4)
- TCR-ALLO cells + TOOLBOX (n=3)
- - - no treatment (n=1)

ALLO

- **Novel TOOL X** enhanced anti-tumor efficacy of TCR-ALLO cells to 100% survival
- TCR-ALLO cell competitors have not hit the clinic or shown comparable preclinical mouse data
- Preliminary results indicate in vivo PoC for **first-in-class TCR-ALLO cell platform**

CAPTAIN T CELL's TRACTION



MILESTONES AND VALUE INFLECTION POINTS

Budget: €20M to reach:
AUTO: clinical data, ALLO: clinic-ready



€16M VC + grants
Join us!



First patient in (AUTO)

Uniklinikum
Erlangen



Dr. Busse
Prof. Keller



UNIKLINIK
KÖLN



Uniklinikum
Würzburg



Universitätsklinikum
Tübingen

2025

2026

2027

2028



IMPD filing
of FiH clinical trial
(AUTO)



1. **Clinical data (AUTO)**
2. **Off-the-shelf
program clinic-ready
(ALLO)**



www.captaintcell.com

felix.lorenz@captaintcell.com

